Clinical Drug Investigation

, Volume 32, Issue 2, pp 139–144

Diagnosis of Depression and Use of Antidepressant Pharmacotherapy Among Adults in the United States

Does a Disparity Persist by Ethnicity/Race?
  • David A. Sclar
  • Linda M. Robison
  • Jennifer M. Schmidt
  • Kurt A. Bowen
  • Leigh V. Castillo
  • Ambartsum M. Oganov
Short Communication

Abstract

Background and Objective: Both the rate of diagnosis of depression in the US and the rate of prescribing an antidepressant for its treatment have increased substantially over the past two decades. Previous research has also indicated that the rates of diagnosis and treatment of depression with an antidepressant vary widely by ethnicity/race. The objective of this study was to discern ethnic/race-specific (non-Hispanic Black; Hispanic; non-Hispanic White) population-adjusted rates of US office-based physician-patient encounters (office-based visits) documenting a diagnosis of depression, and the extent of the use of antidepressant pharmacotherapy for its treatment.

Methods: Data from the US National Ambulatory Medical Care Survey (NAMCS) for the years 1992–1997 and 2003–2008 were utilized for this analysis. The years 1998–2002 were excluded due to the magnitude of missing data for the variable ethnicity. The US NAMCS is a national probability sample designed and conducted by the US National Center for Health Statistics of the US Centers for Disease Control and Prevention. Depression was defined via International Classification of Diseases, 9th Revision, Clinical Modification codes 296.2-296.36; 300.4; 311. Antidepressants were defined as US National Drug Code category 0630 prior to 2005, and category 249 in Lexicon Plus® thereafter. Data were partitioned into six 2-year time intervals for trend analysis of population-adjusted rates (per 100) among patients aged 20–79 years. Rates per 2-year time interval are based on US Census Bureau national resident population estimates for the ethnicity/race categories examined. Comparisons within and across time-frames were assessed by chi-squared (χ2) analysis. The a priori level of significance for all statistical tests was set at p<0.05. Analyses were performed using SAS Release 9.1.3.

Results: Over the 12-year time-frame examined, the rate of office-based visits documenting a diagnosis of depression increased 28.4% for non-Hispanic Whites (from 10.9 to 14.0 per 100; p < 0.001), 54.8% for non-Hispanic Blacks (from 4.2 to 6.5 per 100; p<0.001), and 37.5% for Hispanics (from 4.8 to 6.6 per 100; p < 0.001). The rate of office-based visits with a recorded diagnosis of depression in concert with the prescribing of an antidepressant increased 66.2% for non-Hispanic Whites (from 6.5 to 10.8 per 100; p<0.001), 69.2% for non-Hispanic Blacks (from 2.6 to 4.4 per 100; p < 0.001), and 36.7% for Hispanics (from 3.0 to 4.1 per 100; p<0.001).

Conclusion: By 2003–2004, the population-adjusted rates for non-Hispanic Blacks and Hispanics were similar, and remained so through 2007–2008. However, over the 12-year time-frame examined, the rates for both minority groups were, in each 2-year interval, far less than that observed in non-Hispanic Whites. Disparities remain by ethnicity/race in the diagnosis and treatment of depression in the US.

References

  1. 1.
    Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care. Pharmacoeconomics 1995; 7: 284–91PubMedCrossRefGoogle Scholar
  2. 2.
    Hall RC, Wise MG. The clinical and financial burden of mood disorders: cost and outcome. Psychosomatics 1995; 36Suppl. 2: S11–8PubMedCrossRefGoogle Scholar
  3. 3.
    Johnson J, Weissman M, Klerman GL. Service utilization and social morbidity associated with depressive symptoms in the community. JAMA 1992; 267: 1478–83PubMedCrossRefGoogle Scholar
  4. 4.
    Kessler RC, Berglund P, Demler O, et al. National Comorbidity Survey Replication. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289(23): 3095–105PubMedCrossRefGoogle Scholar
  5. 5.
    Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?J Clin Psychiatry 2003; 64(12): 1465–75PubMedCrossRefGoogle Scholar
  6. 6.
    Andrade L, Caraveo-Anduaga JJ, Berglund P, et al. The epidemiology of major depressive episodes: results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int J Methods Psychiatr Res 2003; 12(1): 3–21PubMedCrossRefGoogle Scholar
  7. 7.
    Olfson M, Marcus SC, Druss B, et al. National trends in the outpatient treatment of depression. JAMA 2002; 287: 203–9PubMedCrossRefGoogle Scholar
  8. 8.
    Skaer TL, Sclar DA, Robison LM, et al. Trend in the use of antidepressant pharmacotherapy and diagnosis of depression in the US: an assessment of office-based visits 1990 to 1998. CNS Drugs 2000; 14: 473–81CrossRefGoogle Scholar
  9. 9.
    Simpson SM, Krishnan LL, Kunik ME, et al. Racial disparities in diagnosis and treatment of depression: a literature review. Psychiatr Q 2007; 78: 3–14PubMedCrossRefGoogle Scholar
  10. 10.
    Sclar DA, Robison LM, Skaer TL. Ethnicity/race and the diagnosis of depression and use of antidepressants by adults in the United States. Int Clin Psychopharmacol 2008; 23: 106–9PubMedCrossRefGoogle Scholar
  11. 11.
    Melfi CA, Croghan TW, Hanna MP, et al. Racial variation in antidepressant treatment in a Medicaid population. J Clin Psychiatry 2000; 61: 16–21PubMedCrossRefGoogle Scholar
  12. 12.
    Sclar DA, Robison LM, Skaer TL, et al. Antidepressant prescribing patterns: a comparison of blacks and whites in a Medicaid population. Clin Drug Investig 1998; 16: 135–40PubMedCrossRefGoogle Scholar
  13. 13.
    Sclar DA, Robison LM, Skaer TL, et al. Ethnicity and the prescribing of antidepressant pharmacotherapy: 1992–1995. Harv Rev Psychiatry 1999; 7: 29–36PubMedGoogle Scholar
  14. 14.
    Skaer TL, Sclar DA, Robison LM, et al. Trends in the rate of depressive illness and use of antidepressant pharmacotherapy by ethnicity/race: an assessment of office-based visits in the United States, 1992–1997. Clin Ther 2000; 22: 1575–89PubMedCrossRefGoogle Scholar
  15. 15.
    National Center for Health Statistics. Centers for Disease Control and Prevention. U.S. NAMCS: National Ambulatory Medical Care Survey, 1992–1997,2003–2008 [online]. Available from URL: http://www.cdc.gov/nchs/ahcd.htm [Accessed 2011 Oct 10]
  16. 16.
    Bryant E, Shimizu I. Sampling design, sampling variance, and estimation procedures for the National Ambulatory Medical Care Survey. National Center for Health Statistics. Vital Health Stat 1988; 2: 1–39Google Scholar
  17. 17.
    U.S. Public Health Service and Health Care Financing Administration. International classification of diseases, 9th revision, clinical modification, volume 1. DHHS publication no. (PHS) 89-1260. Washington, DC: Public Health Service, 1989Google Scholar
  18. 18.
    Food and Drug Administration. National Drug Code Directory, 1995 edition. Washington, DC: Public Health Service, 1995Google Scholar
  19. 19.
    Koch H, Campbell W. The collection and processing of drug information. National Ambulatory Medical Care Survey, 1980. National Center for Health Statistics, Vital Health Stat 1982; 2: 1–90Google Scholar
  20. 20.
    Cerner Multum, Inc. [online]. Available from URL: http://www.multum.com/Lexicon.htm, [Accessed 2011 Feb 23]
  21. 21.
    U.S. Census Bureau. National population estimates for the 1990’s: monthly postcensal resident population, by single year of age, sex, race, and Hispanic origin. Washington, DC: Population Estimates Program Population Division [online]. Available from URL: http://www.census.gov/population/www/estimates/nat_90s_1.html [Accessed 2007 Jun 6]
  22. 22.
    U.S. Census Bureau. National population estimates — characteristics. National sex, age, race and Hispanic origin: April 1, 2000 to July 1, 2008. Washington, DC: Population Estimates Program Population Division [online]. Available from URL: http://www.census.gov/popest/national/asrh/NC-EST2008-asrh.html [Accessed 2010 Oct 22]
  23. 23.
    Sclar DA, Skaer TL, Robison LM, et al. Economic appraisal of citalopram in the management of single-episode depression. J Clin Psychopharmacol 1999; 19Suppl. 1: 47S–54SPubMedCrossRefGoogle Scholar
  24. 24.
    Strothers 3rd HS, Rust G, Minor P, et al. Disparities in antidepressant treatment in Medicaid elderly diagnosed with depression. J Am Geriatr Soc 2005; 53(3): 456–61PubMedCrossRefGoogle Scholar
  25. 25.
    Stockdale SE, Lagomasino IT, Siddique J, et al. Racial and ethnic disparities in detection and treatment of depression and anxiety among psychiatric and primary health care visits, 1995–2005. Medical Care 2008; 46(7): 668–77PubMedCrossRefGoogle Scholar
  26. 26.
    Sclar DA, Skaer TL, Robison LM, et al. Economic outcomes with antidepressant pharmacotherapy: a retrospective intent-to-treat analysis. J Clin Psychiatry 1998; 59Suppl. 2: 13–7PubMedGoogle Scholar
  27. 27.
    Skaer TL, Sclar DA, Robison LM, et al. The need for an iterative process for assessing economic outcomes associated with selective serotonin reuptake inhibitors. Pharmacoeconomics 2000; 18: 205–14PubMedCrossRefGoogle Scholar
  28. 28.
    Sclar DA, Robison LM, Skaer TL, et al. What factors influence the prescribing of antidepressant pharmacotherapy? An assessment of national office-based encounters. Int J Psychiatry Med 1998; 28: 447–59CrossRefGoogle Scholar
  29. 29.
    Robison LM, Skaer TL, Sclar DA, et al. Is attention-deficit/hyperactivity disorder increasing among girls in the U.S.? Trends in diagnosis and the prescribing of stimulants. CNS Drugs 2002; 16: 129–37PubMedCrossRefGoogle Scholar
  30. 30.
    González HM, Vega WA, Williams DR, et al. Depression care in the United States: too little for too few. Arch Gen Psychiatry 2010; 67: 37–46PubMedCrossRefGoogle Scholar
  31. 31.
    Alegria M, Chatterji P, Wells K, et al. Disparity in depression treatment among racial and ethnic minority populations in the United States. Psych Services 2008; 59: 1264–72CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2012

Authors and Affiliations

  • David A. Sclar
    • 1
    • 2
    • 3
    • 4
    • 5
  • Linda M. Robison
    • 1
    • 2
  • Jennifer M. Schmidt
    • 1
  • Kurt A. Bowen
    • 1
  • Leigh V. Castillo
    • 1
  • Ambartsum M. Oganov
    • 1
  1. 1.Pharmacoeconomics and Pharmacoepidemiology Research UnitWashington State UniversitySpokaneUSA
  2. 2.Department of Health Policy and AdministrationCollege of Pharmacy, Washington State UniversitySpokaneUSA
  3. 3.Department of PharmacotherapyWashington State UniversitySpokaneUSA
  4. 4.Department of StatisticsWashington State UniversitySpokaneUSA
  5. 5.Washington Institute for Mental Illness Research and TrainingSpokaneUSA

Personalised recommendations